Immunotherapies that work through inhibiting the PD-L1/PD-1 axis have been successful in inducing clinical responses in patients with different malignancies, including cutaneous melanoma, non-small cell lung cancer, and bladder cancer [21–23]. Here, CD274 is linked to urinary bladder carcinoma.